Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, 200000, China
Location status: Recruiting
NCT Number: NCT07239895
Bronchiolitis obliterans (BO) is a chronic lung disease which was initiated with injury of the bronchiolar epithelium and resulted in nonuniform luminal obliteration or narrowing. Among children, the most common form of BO is post-infectious BO with a lack of treatment guidelines or standard therapy. In this study, an open, single-armed study is performed to preliminarily evaluate the safety and efficacy of airway basal stem cells on treatment of pediatric BO.
Interested in participating?
Request Info28 day–18 year
All sexes
Interventional
Early Phase 1
Shanghai, 200000, China
Location status: Recruiting
The study is co-sponsored by Regend Therapeutics and Shanghai Children's Hospital.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Airway Basal Stem Cells
Time frame: 12 and 24 weeks after treatment
Cough, wheezing, respiratory rate are included in clinical symptomes. Both status and frequency would be evaluated.
Time frame: 24 weeks after treatment
Oxygen saturation (SpO₂), oxygen therapy settings, and daily duration of oxygen therapy would be evaluated.
Time frame: 24 weeks after treatment
Rate of weight gain, time of independent activity are evaluated as general condition.
Time frame: 12 and 24 weeks after treatment
DLCO is a measure of the conductance of CO across the alveolar-capillary membrane and its binding with hemoglobin.
Time frame: 12 and 24 weeks after treatment
FEV1 is the volume of breath exhaled with effort in one second.
Time frame: 12 and 24 weeks after treatment
FVC is the full amount of air that can be exhaled with effort in a complete breath
Time frame: 24 weeks after treatment
HRCT scan is a type of CT scan that shows detailed pictures of lungs
Time frame: 24 weeks after treatment
Frequency and severity of events will be evaluated
Contact information is provided by the study sponsor or research team.
Regend Therapeutics
Industry
Exploratory Study of Airway Basal Stem Cells on Treatment of Pediatric Bronchiolitis Obliterans
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07434869
Behavior, Bronchial Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT04098445
Blood Platelet Disorders, Bronchial Diseases
San Francisco, California, United States
View Trial DetailsNCT05922761
Bronchial Diseases, Bronchiolitis
Stanford, California, United States
View Trial DetailsNCT04604522
Bronchial Diseases, Bronchiolitis
Houston, Texas, United States
View Trial Details